180 related articles for article (PubMed ID: 35583540)
1. Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
Sasaki R; Fukushima M; Haraguchi M; Honda T; Miuma S; Miyaaki H; Nakao K
Medicine (Baltimore); 2022 May; 101(19):e29289. PubMed ID: 35583540
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.
Choi NR; Kim JY; Hong JH; Hur MH; Cho H; Park MK; Kim J; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
BMC Gastroenterol; 2022 Mar; 22(1):135. PubMed ID: 35337274
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.
Chen B; Zhang L; Cheng J; Wu T; Lei J; Yang X; Zhang R; Safadi R; Li Y; Si T; Lu Y
Drug Des Devel Ther; 2022; 16():4429-4437. PubMed ID: 36597443
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
[TBL] [Abstract][Full Text] [Related]
6. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
12. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
Briggs A; Daniele B; Dick K; Evans TRJ; Galle PR; Hubner RA; Lopez C; Siebert U; Tremblay G
Br J Cancer; 2020 Jun; 122(12):1754-1759. PubMed ID: 32265508
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study.
Simmons DJ; Valerio SJ; Thomas DS; Healey MJ; Jiang Z; Levingston Mac Leod JM; Lin Y; Sah J
Adv Ther; 2024 Apr; 41(4):1711-1727. PubMed ID: 38443649
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib: A Review in Hepatocellular Carcinoma.
Al-Salama ZT; Syed YY; Scott LJ
Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
[TBL] [Abstract][Full Text] [Related]
16. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
17. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T; Kudo M; Ikeda K; Izumi N; Tateishi R; Ikeda M; Aikata H; Kawaguchi Y; Wada Y; Numata K; Inaba Y; Kuromatsu R; Kobayashi M; Okusaka T; Tamai T; Kitamura C; Saito K; Haruna K; Okita K; Kumada H
J Gastroenterol; 2020 Jan; 55(1):113-122. PubMed ID: 31720835
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
19. Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
Takada H; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Muraoka M; Suzuki Y; Sato M; Takano S; Fukasawa M; Yamaguchi T; Maekawa S; Takahashi K; Uchimura K; Enomoto N
Oncology; 2023; 101(10):609-623. PubMed ID: 37279708
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
Kim JJ; McFarlane T; Tully S; Wong WWL
Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
